Kinin B 1 Receptor Antagonists Containing α-Methyl- l -Phenylalanine: In Vitro and In Vivo Antagonistic Activities

Publisher Website
Google Scholar
Abstract
—To protect from metabolism and to improve potency of the AcLys-[ d -βNal 7 ,Ile 8 ]desArg 9 -bradykinin (BK) (R 715), we prepared and tested 3 analogues containing α-methyl- l -Phe ([ α Me]Phe) in position 5: these are the AcLys-[( α Me)Phe 5 , d -βNal 7 ,Ile 8 ]desArg 9 BK (R 892), Lys-Lys-[( α Me)Phe 5 , d -βNal 7 ,Ile 8 ]desArg 9 BK (R 913), and AcLys-Lys-[( α Me)Phe 5 , d -βNal 7 ,Ile 8 ]desArg 9 BK (R 914). The new compounds were tested against the contractile effect induced by desArg 9 BK on 2 B 1 receptor bioassays, the human umbilical vein, and the rabbit aorta. Their antagonistic activities were compared with those of the early prototypes (Lys-[Leu 8 ]desArg 9 BK and [Leu 8 ]desArg 9 BK) and with other recently described peptide antagonists. The 3 ( α Me)Phe analogues showed high antagonistic potencies (pA 2 ) at both the human (8.8, 7.7, and 8.7, respectively) and rabbit (8.6, 7.8, and 8.6, respectively) B 1 receptors. No antagonistic effects (pA 2 600 nmol/kg IV). Conversely, the peptide antagonists Lys-Lys-[Hyp 3 ,Igl 5 , d -Igl 7 ,Oic 8 ]desArg 9 BK (B 9858) and d Arg-[Hyp 3 ,Thi 5 , d -Tic 7 ,Oic 8 ] desArg 9 BK (S 0765) showed dual B 1 /B 2 receptor antagonism in vitro and in vivo. It is concluded that R 892 and congeners provide selective, highly potent, and metabolically stable B 1 kinin receptor antagonists that can be useful for the assessment of the physiological and pathological roles of kinin B 1 receptors.